Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice.

van Lümig PP, Driessen RJ, Kievit W, Boezeman JB, van de Kerkhof PC, de Jong EM.

J Am Acad Dermatol. 2013 Jan;68(1):57-63. doi: 10.1016/j.jaad.2012.05.040. Epub 2012 Jul 28.

PMID:
22846689
2.

Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.

Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM.

Br J Dermatol. 2009 Mar;160(3):670-5. doi: 10.1111/j.1365-2133.2008.09019.x. Epub 2008 Jan 28.

PMID:
19210502
3.

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.

Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.

Arch Dermatol. 2007 Jun;143(6):719-26.

PMID:
17576937
4.

[Clinical experience with etanercept in the treatment of psoriasis].

Martín B, Sánchez-Carazo JL, Pérez-Ferriols A, Laguna C, Oliver V, Alegre V.

Actas Dermosifiliogr. 2008 Sep;99(7):540-5. Spanish.

PMID:
18682167
5.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

6.

Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.

Mazzotta A, Esposito M, Costanzo A, Chimenti S.

Am J Clin Dermatol. 2009;10(5):319-24. doi: 10.2165/11310770-000000000-00000.

PMID:
19658444
7.

Two years of experience with etanercept in recalcitrant psoriasis.

Ahmad K, Rogers S.

Br J Dermatol. 2007 May;156(5):1010-4. Epub 2007 Apr 4.

PMID:
17408393
8.

Our experience with etanercept in the treatment of psoriasis.

Kokelj F, Miertusova Tothova S, Patamia M, Trevisan G.

Acta Dermatovenerol Croat. 2006;14(4):241-5.

PMID:
17311738
9.

Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation.

Arcese A, Aste N, Bettacchi A, Camplone G, Cantoresi F, Caproni M, D'Amico D, Fabbri P, Filosa G, Galluccio A, Hansel K, Lisi P, Micali G, Musumeci ML, Nicolini M, Parodi A, Patania M, Pezza M, Potenza C, Richetta A, Simonacci M, Trevisan P, Valenti G, Calvieri S.

Clin Drug Investig. 2010;30(8):507-16. doi: 10.2165/11537470-000000000-00000.

PMID:
20586516
10.

The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.

Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S, Economopoulos T, Stavrianeas NG, Katsambas A.

Clin Exp Dermatol. 2011 Dec;36(8):845-50. doi: 10.1111/j.1365-2230.2011.04131.x. Epub 2011 Jul 25.

PMID:
21790728
11.

Etanercept treatment for children and adolescents with plaque psoriasis.

Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A; Etanercept Pediatric Psoriasis Study Group..

N Engl J Med. 2008 Jan 17;358(3):241-51. doi: 10.1056/NEJMoa066886.

12.

Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.

Leonardi C, Strober B, Gottlieb AB, Elewski BE, Ortonne JP, van de Kerkhof P, Chiou CF, Dunn M, Jahreis A.

J Drugs Dermatol. 2010 Aug;9(8):928-37.

PMID:
20684143
13.

[Long-term safety and efficacy of etanercept in the treatment of psoriasis].

Zaragoza V, Pérez A, Sánchez JL, Oliver V, Martínez L, Alegre V.

Actas Dermosifiliogr. 2010 Jan-Feb;101(1):47-53. Spanish.

PMID:
20109392
14.

The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab.

Papoutsaki M, Talamonti M, Giunta A, Costanzo A, Ruzzetti M, Teoli M, Chimenti S.

Dermatology. 2010;221 Suppl 1:43-7. doi: 10.1159/000316184. Epub 2010 Aug 9.

PMID:
20733314
15.

Etanercept combined with methotrexate for high-need psoriasis.

Driessen RJ, van de Kerkhof PC, de Jong EM.

Br J Dermatol. 2008 Aug;159(2):460-3. doi: 10.1111/j.1365-2133.2008.08669.x. Epub 2008 Jun 28.

PMID:
18547310
16.

Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.

Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.

J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S101-11.

PMID:
16488320
17.

Initial experience with routine administration of etanercept in psoriasis.

de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD.

Br J Dermatol. 2006 Oct;155(4):808-14.

PMID:
16965432
19.

Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study.

Mazzotta A, Esposito M, Schipani C, Chimenti S.

J Dermatolog Treat. 2009;20(6):354-8. doi: 10.3109/09546630902936752.

PMID:
19954392
20.

Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.

Landells I, Paller AS, Pariser D, Kricorian G, Foehl J, Molta C, Freundlich B.

Eur J Dermatol. 2010 May-Jun;20(3):323-8. doi: 10.1684/ejd.2010.0911. Epub 2010 Feb 25.

PMID:
20185386

Supplemental Content

Support Center